The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.

Start Date01 Mar 2025

Sponsor / Collaborator

University of Miami

[+1]

NCT06710990

/ Not yet recruitingPhase 1

A Multicenter, Open-label, Fixed-sequence Study to Evaluate Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.

Start Date01 Dec 2024

Sponsor / Collaborator

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

CTR20242799

/ CompletedNot Applicable

达芦那韦片在健康受试者中的单中心，随机、开放、单次给药、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-sequence, two-period, double-crossover, fasting and fed bioequivalence study of darunavir tablets in healthy subjects

主要研究目的：以江苏艾迪药业股份有限公司生产的达芦那韦片为受试制剂，以Janssen-Cilag International NV持证的达芦那韦片（商品名：Prezista®，600 mg）为参比制剂，通过单中心、随机、开放、单次给药、两序列、两周期、双交叉临床研究来评价两种制剂在空腹及餐后条件下的人体生物等效性。次要研究目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

The main purpose of the study is to use Darunavir Tablets produced by Jiangsu Aidi Pharmaceutical Co., Ltd. as the test preparation and Darunavir Tablets (trade name: Prezista®, 600 mg) licensed by Janssen-Cilag International NV as the reference preparation. The bioequivalence of the two preparations under fasting and postprandial conditions is evaluated through a single-center, randomized, open, single-dose, two-sequence, two-period, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date14 Sep 2024

Sponsor / Collaborator

Jiangsu Aidea Pharmaceutical Co., Ltd.

100 Clinical Results associated with Ritonavir

100 Translational Medicine associated with Ritonavir

100 Patents (Medical) associated with Ritonavir

13,894

Literatures (Medical) associated with Ritonavir

31 Dec 2025·ANNALS OF MEDICINE

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Article

Author: Cuccurullo, F. ; Buonomo, A. R. ; Scotto, R. ; D’Agostino, A. ; Palmieri, S. ; Viceconte, G. ; Silvitelli, M. ; Grimaldi, F. ; Moccia, M. ; Mercinelli, S. ; Gentile, I. ; Pietroluongo, D. ; Gravetti, A. ; Trastulli, F.

BACKGROUND:

Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.

RESEARCH DESIGN AND METHODS:

We performed an observational, prospective study, enrolling immunocompromised outpatients with mild-to-moderate COVID-19, treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptom onset. Primary outcome was hospitalization within 30 days. Secondary outcomes were: needing for oxygen therapy; development of persistent infection; death within 60 days and reinfection or relapse within 90 days.

RESULTS:

We enrolled 52 patients. No patient was hospitalized within 30 days of disease onset, required oxygen administration, died within 60 days, or experienced a reinfection or clinical relapse within 90 days.The clearance rates were 67% and 97% on the 14th day after the end of therapy and at the end of the follow-up period, respectively.Factors associated with longer infection were initiation of therapy 3 days after symptom onset and enrollment for more than 180 days from the beginning of the study. However, only the latter factor was independently associated with a longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants.

CONCLUSIONS:

Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19, and development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors

Article

Author: Gerdesköld Rappe, Christian ; Aldvén, Martina ; Mugwagwa, Tendai ; Nilsson, Fredrik

AIMS:

Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of adult patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for 54 patient cohorts, specified according to age, vaccination status and comorbidity burden.

MATERIALS AND METHODS:

A previously published and validated cost-effectiveness model was utilized and adapted to the Swedish setting. The model used a short-term decision-tree (1 year) followed by a lifetime 2-state Markov model. The short-term decision-tree captured costs and outcomes associated with the primary infection. Post-acute COVID-19 syndrome was only considered in terms of quality-of-life decrements for one year. Baseline hospitalization and mortality risks were taken from a Swedish, nationwide, uniquely granular, Omicron-era, real-world study. NMV/r effectiveness were taken from an Omicron-era US real-world study. Remaining inputs were informed by previous COVID-19 studies and publicly available Swedish sources.

RESULTS:

The incremental cost-effectiveness ratios (ICERs) showed a large variation ranging from almost nine million SEK for some of the youngest cohorts to being dominant (i.e. cost-saving with higher gains in quality-of-life vs standard of care) for twelve elderly cohorts. In general, higher age in combination with non-recent (>180 days) or no vaccination led to lower ICERs. Specifically, NMV/r was cost-effective for all but one patient cohorts at least 70 years old, and for most patient cohorts 60-69 years old.

LIMITATIONS:

As the COVID-19 landscape changes, symptom burden and baseline risks constantly change. Thus, the cost-effectiveness of NMV/r will change with time. However, the future risks could be related to the risks in the current study, and thus remain useful for decision makers.

CONCLUSIONS:

This study shows that NMV/r is a cost-effective or even cost-saving treatment option for many patient cohorts, including most elderly and not-recently vaccinated patients with at least some comorbidity burden.

01 May 2025·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition

Article

Author: Garg, Mohit ; Vasan, Seshadri S ; Sankaranarayanan, Murugesan ; Muzaffar-Ur-Rehman, Mohammed ; Kuthe, Pranali Vijaykumar ; Chandu, Ala ; Chougule, Kishor Suryakant

The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.

361

News (Medical) associated with Ritonavir

22 Jan 2025

·www.prnewswire.com

Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held in San Francisco from January 13 to 15. The company introduced a "new paradigm in cancer treatment," shifting from intravenous chemotherapy to patient-centered oral chemotherapy. Technological Innovation: OTX-M Based on Organic-Inorganic Hybrid Drug Delivery Technology OTX-M was developed using the patented organic-inorganic hybrid oral drug delivery technology of Hyundai ADM's affiliated company, CNPharm. Unlike other oral anti-cancer drugs that failed to address drug-drug interaction issues, OTX-M enhances the bioavailability of docetaxel by more than 1,600 times without relying on metabolic inhibitors such as P-gp inhibitors or ritonavir. This breakthrough effectively resolves the challenge of low bioavailability while eliminating concerns about drug interactions. Preclinical Study Results Identify the Optimal Regimen as One Daily Dose at a Moderate Dosage The preclinical study systematically evaluated the effects of varying dosages (low, moderate, and high) and dosing frequencies, assessing anti-tumor efficacy and safety, as measured by weight changes. Low doses administered twice daily showed a tumor inhibition rate of 61.4%, with minimal side effects and stable weight maintenance. Moderate doses administered once daily achieved a tumor inhibition rate of 82.83%, demonstrating the best balance between anti-tumor efficacy and weight stability. High doses administered four times per week achieved the highest tumor inhibition rate of 92.81%. However, weight loss and increased risk of side effects made this approach unsuitable for long-term cancer treatment. The study demonstrated the dose-dependent anti-tumor efficacy of OTX-M, highlighting its excellent safety profile and low risk of side effects. A comprehensive analysis determined that a once-daily moderate dosage offers the optimal balance between efficacy and safety. The Potential of OTX-M in the Global Cancer Treatment Market OTX-M is expected to provide greater patient convenience and economic advantages, with the potential to rapidly replacing the current market dominated by injectable chemotherapy drugs. Research by Rutgers University and Chung-Ang University suggests that oral anti-cancer therapies can reduce treatment costs by 59.9% compared to injectable chemotherapies. This cost-effectiveness makes them an ideal solution for underdeveloped regions with limited medical resources. Additionally, the ability for patients to self-administer the medication at home, without the need for hospital visits, provides significant benefits for both patients and healthcare systems. Global Industry Experts Highlight OTX-M's Paradigm-Shifting Potential A lead researcher from the new drug development division of a global pharmaceutical company, attending the Biotech Showcase commented, "The transition of taxane-based drugs, such as docetaxel and paclitaxel, into oral formulations has been a long-standing challenge that many pharmaceutical companies have attempted but failed to overcome. OTX-M represents the first example of successfully addressing both bioavailability and safety concerns. This technology could be a game-changer for cancer treatment and is expected to establish itself as an oral anti-cancer therapy in the global market following clinical trials in the United States." Hyundai ADM's Commitment to Innovation in Cancer Treatment Hyundai ADM's CEO, Taek-Sung Kim, stated, "OTX-M is an innovative treatment that converts intravenous chemotherapy drugs into oral therapies with lowered side effects, significantly improving patient convenience and quality of life. We aim to usher in an era where cancer can be managed as a chronic condition, like diabetes or hypertension, and play a leading role in the global anti-cancer market." About Hyundai ADM Bio and Hyundai Bioscience Hyundai ADM Bio is a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea. ADM Korea Inc. is listed on the KOSDAQ market (symbol: 187660). Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. SOURCE Hyundai ADM Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

08 Jan 2025

·www.drugs.com

Extended Nirmatrelvir/Ritonavir Beneficial for Some With Long COVID

WEDNESDAY, Jan. 8, 2025 -- Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series published online Jan. 6 in Communications Medicine . Alison K. Cohen, Ph.D., M.P.H., from the University of California San Francisco, and colleagues documented a case series of 13 individuals with long COVID who initiated extended courses (more than five days; range, 7.5 to 30 days) of oral nirmatrelvir/ritonavir outside of and within (11 and two individuals, respectively) the context of an acute severe acute respiratory syndrome coronavirus 2 infection. The researchers found that some of those taking an extended course of nirmatrelvir/ritonavir outside the context of an acute infection experienced a meaningful reduction in symptoms, but not all benefits persisted. No effect on symptoms was experienced by the other individuals in this group. Due to intense stomach pain, one participant stopped taking the medication early. Both participants who took an extended course of nirmatrelvir/ritonavir within the context of an acute reinfection reported eventually returning to their pre-reinfection baseline. "These cases provide strong rationale for the ongoing study of antivirals for long COVID to determine if, when, and how they should be used in this patient population," the authors write. One author disclosed ties to Gilead Sciences and AstraZeneca. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

24 Dec 2024

·www.businesswire.com

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

WATERTOWN, Mass.--( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the ’953 Patent”) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). The Court issued a summary judgment decision granting Pfizer’s motion that the ‘953 Patent is invalid. In its decision, the Court also denied Enanta’s partial motion for summary judgment of infringement as moot in light of its allowance of summary judgment on invalidity. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit. "The U.S. patent system and its protection of important innovations have enabled the robust development of new medicines and spurred growth in the biotechnology industry. We are proud of the impact our strong history of drug discovery work with protease inhibitors has had on antiviral treatments and the thousands of patients that have been treated with therapies using our patented inventions,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals, Inc. “We are disappointed with the Court’s ruling. We believe strongly in the merits of our case, and, through the appeal process, we will continue to defend our inventions from unlawful infringement.” Enanta maintains its commitment to avoid attempting to impede the production, sale or distribution of Paxlovid. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. Forward-Looking Statements This press release contains forward-looking statements, including statements with respect to Enanta’s suit against Pfizer, Inc. in the United States District Court for the District of Massachusetts seeking damages for patent infringement. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including the patent at issue in the Pfizer litigation, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta’s senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta’s reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

Patent Infringement

100 Deals associated with Ritonavir

External Link

KEGG	Wiki	ATC	Drug Bank
D00427	Ritonavir	J05AE03	DB00503

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	US	AbbVie, Inc.	01 Mar 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	NDA/BLA	FR	Ascletis Pharma, Inc.	13 Feb 2022
COVID-19	NDA/BLA	DE	Ascletis Pharma, Inc.	13 Feb 2022
COVID-19	NDA/BLA	IE	Ascletis Pharma, Inc.	13 Feb 2022
COVID-19	NDA/BLA	GB	Ascletis Pharma, Inc.	13 Feb 2022
Pseudohyperkalemia Cardiff	Phase 2	-	Ascletis Pharmaceuticals Co.,Ltd.	01 Jan 2016
Thrombasthenia	Phase 2	-	Ascletis Pharmaceuticals Co.,Ltd.	01 Jan 2016
Hepatitis C, Chronic	Phase 2	-	AbbVie, Inc.	01 Aug 2012
Chronic hepatitis C genotype 3	Phase 2	-	AbbVie, Inc.	01 Sep 2011
Chronic hepatitis C genotype 1	Phase 2	US	AbbVie, Inc.	01 Oct 2010
AIDS-related Kaposi Sarcoma	Phase 2	AU	Abbott Laboratories	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05576662 (STOP-PASC, CTgov)	Phase 2	Post Acute COVID 19 Syndrome	168	Nirmatrelvir+Ritonavir (Nirmatrelvir Plus Ritonavir)	wuyzztkath(xigawdzcrz) = hztabkrqiy smmbojrmax (wgdnvslwkr, atxzqmvqga - ximgpshddr) View more	-	25 Sep 2024
				Placebo+Ritonavir (Placebo Plus Ritonavir)	wuyzztkath(xigawdzcrz) = aydhbjozkp smmbojrmax (wgdnvslwkr, kktcgrcnqq - lzmuolicvb) View more
NCT05011513 (EPIC-SR, Pubmed) Manual	Phase 2/3	COVID-19	1,288	Nirmatrelvir-riritonavir	ivzxqviiuz(vuilqwnjta) = fjkfpemtzu rqoihsarer (mcqjhcyqqn ) View more	Negative	04 Apr 2024
				Placebo	ivzxqviiuz(vuilqwnjta) = qyykvnoucs rqoihsarer (mcqjhcyqqn ) View more
NCT05129475 (CTgov)	Phase 1	-	12	PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fed)	rcjkoxzbui(dngqrcefrf) = mbpocvqydt ivqwtccyzf (niirjndcnf, niyeavtacr - ulmzxfhwcx) View more	-	05 Oct 2023
				PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fasted)	rcjkoxzbui(dngqrcefrf) = cardphslah ivqwtccyzf (niirjndcnf, frakjryitj - qxmqynxjky) View more
EPICOVIDEHA (EHA2023)	Not Applicable	COVID-19	1,859	Nirmatrelvir/ritonavir	lsxfvbkpcc(ftiiwgkygy): aOR = 3.624 (95% CI, 1.619 - 8.109) View more	-	08 Jun 2023
				No nirmatrelvir/ritonavir
P374 (EBMT2023)	Not Applicable	severe lymphopenia	29	Nirmatrelvir/ritonavir	dqhlvjlcfp(vpnbbomspx) = egnitkegol aejixyowum (apxbmrjwpo ) View more	Positive	23 Apr 2023
NCT01281813 (TMC114IFD3001, CTgov)	Phase 3	HIV Infections	145	Rtv+DRV (Continued Treatment With DRV in Combination With Rtv:Children Less Than (<) 12 Years)	svsavpuhzg(wyvwobbmun) = lhvosxpabd mcetkoayzd (jwnbityiry, cmkvgjtaei - zzejtyileb) View more	-	31 Oct 2022
				Rtv+DRV (Continued Treatment With DRV in Combination With Rtv: Adolescents (12-17 Years))	svsavpuhzg(wyvwobbmun) = szsiptasgu mcetkoayzd (jwnbityiry, jekjffuvcx - zdandxafds) View more
ISTH2022	Not Applicable	COVID-19	464	Edoxaban	hvoqhibrfg(ygbxhiezdm) = snbiyfyemc cynqdqecvz (qttmvutmnx ) View more	-	09 Jul 2022
				LMWH	rcxospaiys(nwwkdukusu) = nfajycdyfr eluvgnpqil (ddwxdxjckh )
NCT04960202 (EPIC-HR, Pubmed) Manual	Phase 3	COVID-19	2,246	Nirmatrelvir+Ritonavir	tfyrktaprs(iuddqxhraa) = vkhgxdiarm iwsqlkyohw (xdpgiehowg ) View more	Positive	16 Feb 2022
				Placebo	tfyrktaprs(iuddqxhraa) = lzljdhenod iwsqlkyohw (xdpgiehowg ) View more
NCT00885495 (CTgov)	Phase 1/2	HIV Infections	17	Rosuvastatin (Rosuvastatin)	lzcajasamo(qriczwkpnc) = oytswqhhlr jfrhligdyw (vobkodxuop, dzqggmqfkp - hupgixllyy) View more	-	19 Jan 2022
				Rosuvastatin+Ritonavir+Darunavir (Rosuvastatin-Darunavir-Ritonavir)	lzcajasamo(qriczwkpnc) = ahzsdoxvbe jfrhligdyw (vobkodxuop, fzlcccooyu - ghspdrptfw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis